EGFR-Mutant Lung Cancer in 2018

Overview

This webinar will review the current data and best practices for treatment of stage IV EGFR mutation-positive lung cancer. It will address how to integrate the changing standards of care for wild-type patients with target-driven cancer algorithms. The following topics will be covered:

  • What are the ideal treatment regimens for 1st line and 2nd line.
  • How do we integrate immune therapy into the care of patients with driver oncogenes.
  • What are the areas of unmet need.

 

Date
May 08, 2018 -
May 08, 2018
Location

Online

At the end of this webinar participants will be able to:

  • Review the current data relative to the treatment of stage IV EGFR mutation-positive lung cancer.
  • Identify and discuss best practices for the treatment of EGFR-mutant lung cancer.
  • Address how to integrate the changing standards of care for wild-type patients with target driven cancer algorithms.
  • Identify areas of unmet needs.

Lecia V. Sequist, MD, MPH
The Landry Family Associate Professor of Medicine, Harvard Medical School Director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital.

Program chair-Ramaswamy Govindan, MD
Director, Section of Medical Oncology Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology Washington University School of Medicine.

For any inquiries, please contact meetings@iaslc.org.

At the end of this webinar participants will be able to:

  • Review the current data relative to the treatment of stage IV EGFR mutation-positive lung cancer.
  • Identify and discuss best practices for the treatment of EGFR-mutant lung cancer.
  • Address how to integrate the changing standards of care for wild-type patients with target driven cancer algorithms.
  • Identify areas of unmet needs.

Lecia V. Sequist, MD, MPH
The Landry Family Associate Professor of Medicine, Harvard Medical School Director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital.

Program chair-Ramaswamy Govindan, MD
Director, Section of Medical Oncology Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology Washington University School of Medicine.

For any inquiries, please contact meetings@iaslc.org.

Share